Supplementary Table S2: Incidence of treatment-related adverse events by maximum grade.

	Cohort 1 (n=4)				
	Grade 1 n (%)	Grade 2 n (%)	Grade 3 n (%)	Grade 4 n (%)	Grade 5 n (%)
Any Treatment Related Adverse Events	2 (50.0)	0	0	0	0
General disorders and administration site conditions	2 (50.0)	0	0	0	0
Fatigue	2 (50.0)	0	0	0	0
Injection site reaction	1 (25.0)	0	0	0	0

	Cohort 2 (n=13)				
	Grade 1 n (%)	Grade 2 n (%)	Grade 3 n (%)	Grade 4 n (%)	Grade 5 n (%)
Any Treatment Related Adverse Events	10 (76.9)	1 (7.7)	1 (7.7)	0	0
Blood and lymphatic system disorders	1 (7.7)	0	0	0	0
Lymphadenopathy	1 (7.7)	0	0	0	0
General disorders and administration site conditions	11 (84.6)	1 (7.7)	0	0	0
Injection site reaction	6 (46.2)	1 (7.7)	0	0	0
Fatigue	6 (46.2)	0	0	0	0
Influenza like illness	2 (15.4)	0	0	0	0
Injection site erythema	1 (7.7)	0	0	0	0
Injection site pain	1 (7.7)	0	0	0	0
Injection site pruritus	1 (7.7)	0	0	0	0
Injection site rash	1 (7.7)	0	0	0	0
Pyrexia	1 (7.7)	0	0	0	0
Infections and infestations	1 (7.7)	0	0	0	0
Oral herpes	1 (7.7)	0	0	0	0
Investigations	0	0	1 (7.7)	0	0
Neutrophil count abnormal	0	0	1 (7.7)	0	0
Musculoskeletal and connective tissue disorders	2 (15.4)	0	0	0	0
Myalgia	2 (15.4)	0	0	0	0

	Cohort 2 (n=13)				
	Grade 1 n (%)	Grade 2 n (%)	Grade 3 n (%)	Grade 4 n (%)	Grade 5 n (%)
Nervous system disorders	1 (7.7)	0	0	0	0
Headache	1 (7.7)	0	0	0	0
Skin and subcutaneous tissue disorders	1 (7.7)	0	0	0	0
Rash	1 (7.7)	0	0	0	0

	Cohort 3 (n=11)				
	Grade 1 n (%)	Grade 2 n (%)	Grade 3 n (%)	Grade 4 n (%)	Grade 5 n (%)
Any Treatment Related Adverse Events	7 (63.6)	4 (36.4)	0	0	0
General disorders and administration site conditions	8 (72.7)	3 (27.3)	0	0	0
Injection site reaction	7 (63.6)	3 (27.3)	0	0	0
Injection site pain	3 (27.3)	0	0	0	0
Fatigue	1 (9.1)	0	0	0	0
Pyrexia	1 (9.1)	0	0	0	0
Musculoskeletal and connective tissue disorders	2 (18.2)	0	0	0	0
Arthralgia	1 (9.1)	0	0	0	0
Muscle spasms	1 (9.1)	0	0	0	0
Myalgia	1 (9.1)	0	0	0	0
Skin and subcutaneous tissue disorders	1 (9.1)	1 (9.1)	0	0	0
Erythema	1 (9.1)	0	0	0	0
Panniculitis	0	1 (9.1)	0	0	0
Skin nodule	1 (9.1)	0	0	0	0

Adverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 13.1.

An adverse event was defined as treatment related if the investigator determined it to be possibly, probably, or definitely related to study drug. Patients who experienced the same event at more than one severity level were counted only once under the maximum severity experienced.